Select therapeutic use:

Bladder, kidney, and other urologic cancers:

Indications for IMFINZI:

Locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

Adult:

Give as IV infusion over 60mins. 10mg/kg every 2 weeks until disease progression or unacceptable toxicity. Dose modifications: see full labeling. Administer corticosteroids for most Grade ≥2 related immune-mediated reactions.

Children:

Not established.

Warnings/Precautions:

Monitor for immune-related pneumonitis, hepatitis (obtain LFTs each cycle), colitis/diarrhea, endocrinopathies (thyroid disorders, adrenal insufficiency, diabetes, hypophysitis/hypopituitarism), rash, nephritis, others; see full labeling for adverse reaction management details. Permanently discontinue if Grade 3/4 pneumonitis, AST or ALT >8×ULN or total bilirubin >5×ULN, concurrent AST or ALT >3×ULN and total bilirubin >2×ULN (with no other cause), Grade 3/4 colitis or diarrhea, creatinine >3×ULN, Grade 3/4 infusion-related reactions, Grade 4 rash/dermatitis, other Grade 4 immune-mediated reactions, persistent Grade 2/3 reactions (except endocrinopathies), recurrent Grade 3/4 reactions, or inability to reduce to ≤10mg/day prednisone or equivalent. Withhold for Grade 2 pneumonitis, AST or ALT >3–8×ULN or total bilirubin >1.5–5×ULN, Grade 2 colitis or diarrhea, Grade ≥2 hypophysitis/hypopituitarism, Grade ≥2 adrenal insufficiency, Grade ≥2 hyperthyroidism, Grade ≥2 type 1 diabetes, creatinine >1.5–3×ULN, Grade 3/4 infection, Grade 2 (if >1 week) or Grade 3 rash. Monitor for infection. Interrupt or slow the infusion rate in patients with mild or moderate infusion reactions. Evaluate for Vogt-Koyanagi-Harada syndrome if uveitis in combination with other immune-mediated reactions occur. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥3 months after the last dose. Pregnancy. Nursing mothers: not recommended (during and for ≥3 months after the last dose).

Pharmacologic Class:

Programmed death-ligand 1 (PD-L1) blocking antibody.

Adverse Reactions:

Fatigue, musculoskeletal pain, constipation, decreased appetite, nausea, peripheral edema, UTI, cough, pneumonitis, upper RTI, dyspnea, rash, alopecia; other immune-related reactions (eg, aseptic meningitis, hemolytic anemia), infusion-related reactions, lab abnormalities.

Generic Availability:

NO

How Supplied:

Single-dose vial (2.4mL, 10mL)—1

Pricing for IMFINZI

500mg/10ml vial (Qty: 2)
Appx. price $7598
GoodRx

Respiratory and thoracic cancers:

Indications for IMFINZI:

Unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed after concurrent platinum-based chemotherapy and radiation. First-line treatment of extensive-stage small cell lung cancer (ES-SCLC), in combination with etoposide and either carboplatin or cisplatin.

Adult:

Give as IV infusion over 60mins. NSCLC: 10mg/kg every 2 weeks until disease progression, unacceptable toxicity, or max 12 months. ES-SCLC (≤30kg): 20mg/kg (with chemotherapy) every 3 weeks for 4 cycles, followed by 20mg/kg every 4 weeks as a single agent; (>30kg): 1500mg (with chemotherapy) every 3 weeks for 4 cycles, followed by 1500mg every 4 weeks as a single agent. Continue until disease progression or unacceptable toxicity. In combination with chemotherapy: give Imfinzi prior to chemotherapy on the same day (see full labeling). Dose modifications: see full labeling. Administer corticosteroids for most Grade ≥2 related immune-mediated reactions.

Children:

Not established.

Warnings/Precautions:

Monitor for immune-related pneumonitis, hepatitis (obtain LFTs each cycle), colitis/diarrhea, endocrinopathies (thyroid disorders, adrenal insufficiency, diabetes, hypophysitis/hypopituitarism), rash, nephritis, others; see full labeling for adverse reaction management details. Permanently discontinue if Grade 3/4 pneumonitis, AST or ALT >8×ULN or total bilirubin >5×ULN, concurrent AST or ALT >3×ULN and total bilirubin >2×ULN (with no other cause), Grade 3/4 colitis or diarrhea, creatinine >3×ULN, Grade 3/4 infusion-related reactions, Grade 4 rash/dermatitis, other Grade 4 immune-mediated reactions, persistent Grade 2/3 reactions (except endocrinopathies), recurrent Grade 3/4 reactions, or inability to reduce to ≤10mg/day prednisone or equivalent. Withhold for Grade 2 pneumonitis, AST or ALT >3–8×ULN or total bilirubin >1.5–5×ULN, Grade 2 colitis or diarrhea, Grade ≥2 hypophysitis/hypopituitarism, Grade ≥2 adrenal insufficiency, Grade ≥2 hyperthyroidism, Grade ≥2 type 1 diabetes, creatinine >1.5–3×ULN, Grade 3/4 infection, Grade 2 (if >1 week) or Grade 3 rash. Monitor for infection. Interrupt or slow the infusion rate in patients with mild or moderate infusion reactions. Evaluate for Vogt-Koyanagi-Harada syndrome if uveitis in combination with other immune-mediated reactions occur. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for ≥3 months after the last dose. Pregnancy. Nursing mothers: not recommended (during and for ≥3 months after the last dose).

Pharmacologic Class:

Programmed death-ligand 1 (PD-L1) blocking antibody.

Adverse Reactions:

Fatigue, musculoskeletal pain, constipation, decreased appetite, nausea, peripheral edema, UTI, cough, pneumonitis, upper RTI, dyspnea, rash, alopecia; other immune-related reactions (eg, aseptic meningitis, hemolytic anemia), infusion-related reactions, lab abnormalities.

Generic Availability:

NO

How Supplied:

Single-dose vial (2.4mL, 10mL)—1

Pricing for IMFINZI

500mg/10ml vial (Qty: 2)
Appx. price $7598
GoodRx